Daridorexant 50mg Tablets: The Complete UK Guide for 2026

Daridorexant 50mg tablets are the standard adult dose of a newer class of prescription sleep medicine that works by turning down the brain’s wake signal rather than sedating you into unconsciousness. Sold in the UK under the brand name Quviviq, daridorexant is the first insomnia treatment recommended by NICE specifically for long-term insomnia, which makes it fundamentally different from the zopiclone and zolpidem tablets most people have been offered in the past.

If you have spent months or years cycling through short courses of sleeping tablets, over-the-counter antihistamines and sleep trackers without anything sticking, this guide covers what daridorexant 50mg tablets actually do, what the clinical evidence shows, how they compare to older options, what they cost in the UK, and how to access them safely.

What are daridorexant 50mg tablets?

Daridorexant 50mg tablets are a prescription-only medicine licensed in the UK for adults with insomnia where symptoms have been present for at least three months and are having a considerable impact on daytime functioning. They are manufactured by Idorsia Pharmaceuticals and marketed as Quviviq, supplied in blister packs of 30 film-coated tablets.

The 50mg tablet is light orange, arc-triangle shaped, and debossed with 50 on one side and the Idorsia logo on the other. A 25mg strength also exists, in light purple, but 50mg is the dose most adults are prescribed.

The important word in the licence is long-term. Almost every other sleep medicine available in the UK is licensed and recommended for short-term use, typically no more than two to four weeks. Daridorexant was assessed and approved with chronic insomnia in mind, which is a meaningful shift for anyone whose sleep problem has lasted years rather than weeks.

How daridorexant 50mg tablets work

Your brain runs two competing systems. One drives sleep. The other, powered largely by a pair of neuropeptides called orexin A and orexin B, drives wakefulness. In healthy sleep, the wake system quietens down in the evening and the sleep system takes over. In many people with chronic insomnia, that wake system stays switched on when it should be winding down. You are not short of sleep drive. You are stuck in an overactive state of alertness.

Daridorexant is a dual orexin receptor antagonist, usually shortened to DORA. It blocks both orexin receptors with roughly equal potency, reducing wake drive so your natural sleep pressure can take effect. Critically, it does this without altering the architecture of your sleep stages, which is one of the criticisms levelled at older sedatives.

The practical difference matters. Benzodiazepines and Z-drugs such as zopiclone and zolpidem act on GABA receptors to broadly suppress central nervous system activity. That produces sleep, but it is closer to sedation than to natural sleep, and it comes with tolerance, dependence and next-day impairment as the trade-off. Daridorexant works upstream on the specific mechanism that is malfunctioning.

Daridorexant reaches peak blood levels within one to two hours and has an elimination half-life of around eight hours, which is deliberately matched to a normal night’s sleep. The intention is that the drug is largely cleared by the time you need to be functional.

What the clinical evidence shows

Daridorexant was evaluated in two large phase 3 trials across 156 sites in 18 countries, published in The Lancet Neurology in 2022. Study 1 compared daridorexant 50mg and 25mg against placebo over three months. Sleep was measured objectively using polysomnography rather than relying only on what participants reported.

Two primary endpoints were tracked. Wake after sleep onset (WASO) measures how many minutes you spend awake during the night once you have fallen asleep. Latency to persistent sleep (LPS) measures how long it takes to get to sleep in the first place.

All differences shown are least squares mean differences versus placebo and were statistically significant.

The number that deserves the most attention is the last row. The IDSIQ is a validated questionnaire measuring how energetic, tired or sleepy people feel during the day. Daridorexant 50mg was the only dose in the programme to significantly improve daytime functioning as well as night-time sleep. The 25mg dose improved sleep measures but did not deliver the same daytime benefit.

That is the whole point of treating insomnia. Nobody cares about polysomnography readouts. They care about whether they can think clearly at work, drive safely and hold a conversation without their brain fogging over. The 50mg dose is what the evidence supports for that outcome, and pooled dose-response analyses across the phase 2 and phase 3 programme have since confirmed a clear linear relationship between dose and benefit.

A 40-week extension study followed participants out to 12 months. Improvements in self-reported total sleep time and daytime functioning were sustained across the year, with the largest gains in the 50mg group, where mean increases in subjective total sleep time reached roughly 68 to 76 minutes from baseline. Importantly, no evidence of tolerance emerged, meaning the effect did not wear off with continued use.

Daridorexant 50mg versus 25mg: which dose will I be prescribed?

This is one of the most common questions we get, and the answer is more clear-cut than people expect. There is no titration schedule with daridorexant. You do not start low and work up.

Side effect rates did not increase meaningfully at the higher dose in trials. There was no clear dose-relationship for the frequency or severity of adverse reactions, and rates of somnolence and falls at 50mg were comparable to placebo. So the 25mg tablet is not a gentler option chosen for cautious patients. It is a pharmacokinetic adjustment for people whose bodies will clear the drug more slowly.

Your prescriber makes this decision from your consultation. The maximum daily dose is 50mg regardless.

How daridorexant compares to other UK sleep treatments

Who daridorexant 50mg tablets are suitable for

The licence covers adults with insomnia characterised by symptoms present for at least three months with considerable impact on daytime functioning. NICE technology appraisal TA922 narrows this further for NHS prescribing, recommending daridorexant for adults with symptoms on three or more nights per week for at least three months where daytime functioning is considerably affected, and only where CBT-I has been tried without success or is unavailable or unsuitable.

Daridorexant is not appropriate if you have narcolepsy, a known allergy to daridorexant, severe liver impairment, or if you take a strong CYP3A4 inhibitor such as ketoconazole, itraconazole or clarithromycin. It is not licensed for anyone under 18.

Additional caution applies if you have a history of depression or suicidal thoughts, a history of drug or alcohol misuse, breathing difficulties including severe COPD or obstructive sleep apnoea, or if you are over 65 with a history of falls. It is not recommended in pregnancy. Data in people over 75 is limited.

One point worth raising with your prescriber honestly: if you snore heavily, wake gasping, or your partner has noticed you stop breathing at night, undiagnosed sleep apnoea may be the real problem. Treating that as insomnia will not fix it, and it needs proper assessment first. Our insomnia treatment page explains how we assess long-term sleep problems and what alternatives exist.

How to take daridorexant 50mg tablets

• One 50mg tablet once per night, taken within 30 minutes of going to bed
• Swallow whole with water; do not crush, split or chew
• Allow at least seven hours before you need to be awake and alert
• Avoid taking it immediately after a large meal, which can delay how quickly it works
• Avoid grapefruit and grapefruit juice in the evening, as these can raise blood levels of the drug
• Do not drink alcohol while taking it
• If you miss a dose, skip it entirely and take the next one the following evening. Never take it during the night.

Consistency matters more than people expect. An exploratory weekly analysis of the phase 3 data showed benefits building over successive weeks rather than appearing fully formed on night one. Many people notice a difference within the first few nights, but give it a fair run of two to four weeks before judging it, and pair it with a fixed wake time every day including weekends.

Side effects and safety profile

The most frequently reported side effects are headache and somnolence. In trials the majority of adverse reactions were mild to moderate. Other common effects include fatigue, dizziness, nausea and vivid dreams.

Less commonly, sleep paralysis and hypnagogic or hypnopompic hallucinations can occur, mainly in the first few weeks. These are unsettling but not dangerous, and are worth reporting so your treatment can be reviewed. Brief cataplexy-like muscle weakness has also been described.

Hypersensitivity reactions including angioedema have been reported after marketing, so any swelling of the face, lips, tongue or throat, or difficulty breathing, requires immediate medical attention and permanent discontinuation.

On dependence, the picture is genuinely different from Z-drugs. Trials showed no physical dependence, no rebound insomnia and no withdrawal signs on stopping, and no tapering is normally needed. It remains a medicine with some misuse potential that should only ever be taken as prescribed and never shared.

Suspected side effects can be reported through the MHRA Yellow Card Scheme.

What daridorexant 50mg tablets cost in the UK

The NHS list price submitted to NICE is £42 for a pack of 30 tablets, working out at £1.40 per night. The 25mg and 50mg strengths are priced identically, so you are not paying more for the higher dose.

That list price is the reference point, not the retail price. If daridorexant is prescribed on the NHS in England you pay the standard prescription charge unless you are exempt, which for most people is less than the list price. Through a private online pharmacy, the price you pay reflects the medicine cost plus the clinical consultation, dispensing and delivery, so figures vary considerably between providers.

How to get daridorexant 50mg tablets in the UK

There are two legitimate routes.

Through your GP. Daridorexant can be prescribed in primary care in line with NICE TA922, though local formulary positions vary and some areas restrict initiation. Your GP will want to see evidence that CBT-I has been tried or is not accessible, and will review your medication list for interactions.

Through a registered online pharmacy. You complete a clinical consultation, a UK prescriber reviews it, and if daridorexant is safe and appropriate it is dispensed and delivered. A proper service will decline requests that do not meet the clinical criteria and will schedule a review within three months.

What is not legitimate is any site offering daridorexant 50mg tablets without a consultation, or shipping from outside the UK without a prescription. You can verify any UK pharmacy on the General Pharmaceutical Council register, and legitimate online sellers of medicines display the EU common logo linking to their regulator listing.

Daridorexant 50mg tablets: frequently asked questions